BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 257 filers reported holding BIO-TECHNE CORP in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,850,102 | -39.0% | 174,087 | -26.9% | 0.01% | -37.5% |
| Q2 2023 | $19,433,001 | +26.7% | 238,062 | +15.1% | 0.01% | +14.3% |
| Q1 2023 | $15,339,079 | -3.5% | 206,754 | +7.8% | 0.01% | 0.0% |
| Q4 2022 | $15,902,849 | +15.9% | 191,878 | +297.0% | 0.01% | 0.0% |
| Q3 2022 | $13,727,000 | -18.5% | 48,334 | -0.5% | 0.01% | -12.5% |
| Q2 2022 | $16,844,000 | -21.0% | 48,593 | -1.3% | 0.01% | 0.0% |
| Q1 2022 | $21,318,000 | -16.9% | 49,229 | -0.7% | 0.01% | -11.1% |
| Q4 2021 | $25,642,000 | +0.6% | 49,566 | -5.8% | 0.01% | -10.0% |
| Q3 2021 | $25,486,000 | -10.9% | 52,596 | -17.2% | 0.01% | -9.1% |
| Q2 2021 | $28,594,000 | +11.3% | 63,506 | -5.6% | 0.01% | 0.0% |
| Q1 2021 | $25,694,000 | +22.3% | 67,274 | +1.7% | 0.01% | +10.0% |
| Q4 2020 | $21,001,000 | +26.4% | 66,133 | -1.4% | 0.01% | +11.1% |
| Q3 2020 | $16,621,000 | -6.3% | 67,092 | -0.2% | 0.01% | -10.0% |
| Q2 2020 | $17,744,000 | +46.1% | 67,194 | +4.9% | 0.01% | +11.1% |
| Q1 2020 | $12,143,000 | -14.2% | 64,038 | -0.6% | 0.01% | +12.5% |
| Q4 2019 | $14,147,000 | +14.8% | 64,448 | +2.4% | 0.01% | 0.0% |
| Q3 2019 | $12,319,000 | -7.9% | 62,958 | -1.9% | 0.01% | 0.0% |
| Q2 2019 | $13,376,000 | -6.1% | 64,158 | -10.6% | 0.01% | -11.1% |
| Q1 2019 | $14,246,000 | +54.6% | 71,749 | +12.7% | 0.01% | +28.6% |
| Q4 2018 | $9,214,000 | +8.4% | 63,668 | +52.9% | 0.01% | +16.7% |
| Q3 2018 | $8,499,000 | +157.1% | 41,639 | +86.4% | 0.01% | +200.0% |
| Q2 2018 | $3,306,000 | +0.5% | 22,343 | +2.6% | 0.00% | 0.0% |
| Q1 2018 | $3,290,000 | -1.1% | 21,784 | -15.2% | 0.00% | 0.0% |
| Q4 2017 | $3,326,000 | +6.8% | 25,674 | -0.3% | 0.00% | 0.0% |
| Q3 2017 | $3,113,000 | +2.7% | 25,754 | -0.1% | 0.00% | 0.0% |
| Q2 2017 | $3,030,000 | +17.4% | 25,784 | +1.5% | 0.00% | 0.0% |
| Q1 2017 | $2,581,000 | -1.8% | 25,394 | -0.6% | 0.00% | 0.0% |
| Q4 2016 | $2,627,000 | -7.5% | 25,544 | -1.5% | 0.00% | 0.0% |
| Q3 2016 | $2,840,000 | -3.3% | 25,934 | -0.5% | 0.00% | -33.3% |
| Q2 2016 | $2,938,000 | +8.2% | 26,054 | -9.3% | 0.00% | +50.0% |
| Q1 2016 | $2,715,000 | +11.5% | 28,726 | +6.2% | 0.00% | 0.0% |
| Q4 2015 | $2,434,000 | -4.2% | 27,041 | -1.6% | 0.00% | 0.0% |
| Q3 2015 | $2,540,000 | -13.8% | 27,475 | -8.1% | 0.00% | 0.0% |
| Q2 2015 | $2,945,000 | +1.6% | 29,908 | +3.4% | 0.00% | 0.0% |
| Q1 2015 | $2,900,000 | +5.6% | 28,918 | -2.7% | 0.00% | 0.0% |
| Q4 2014 | $2,746,000 | – | 29,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |